1. Scrip
  2. >>Business
  3. >>Deals

EIP And Diffusion Combine To Form CNS Firm With Dementia Focus

Neflamapimod At Heart Of All-Stock Merger

 
• By Ayisha Sharma

The US biotechs are joining forces to form a new, listed company with sufficient cash to advance EIP’s potentially disease-modifying drug candidate through Phase II development in dementia with Lewy bodies, which presents a high unmet need.  

White jigsaw puzzle of the brain with one missing piece out on the side, orange background
More Than One Million People In The US Have Dementia With Lewy Bodies • Source: Shutterstock

Private biotech EIP Pharma, Inc. and publicly traded Diffusion Pharmaceuticals, Inc. are entering an all-stock merger to create a new firm focused on CNS therapeutics with an eye to bringing the first disease-modifying drug for dementia with Lewy bodies (DLB) to the market.

The new company – to be called CervoMed – will continue to trade on the NASDAQ and focus on the advancement of EIP’s pipeline of oral stress kinase inhibitors, including...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Astellas Gets CLDN.18.2-Targeted ADC From China’s Evopoint

 
• By Joseph Haas

Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.

Lilly To Diversify Pain Pipeline With SiteOne Acquisition

 
• By Joseph Haas

Deal snapshot: With several internal non-opioid pain candidates in Phase II or earlier, Lilly looks to add R&D potential in pain with $1bn buyout of SiteOne.

Angelini Advances Brain Health Ambitions With GRIN Pact

 
• By Kevin Grogan

The Italian drugmaker gets rights to Phase III-ready asset radiprodil.

Deal Watch: QurAlis Targets Fragile-X Syndrome In Deals With Quiver, UMass

 
• By Joseph Haas

Plus the end of Sanofi’s six-target alliance with IGM, OmniAb’s deals with Veraxa and Angelini, alliances involving Skye/Arecor, Genprex/UTHealth Houston and more.

More from Business

Loss Of Exclusivity Product Launches To Fuel Aurobindo’s FY26 Europe Growth

 
• By Vibha Ravi

Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now

Korea Q1 Roundup: Mixed Earnings, Gearing For Possible US Tariffs

 
• By Jung Won Shin

South Korean biopharma companies report a mostly solid first quarter, marked by US growth for original drugs, with several also making preparations for possible US pharma tariffs.

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

 
• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.